期刊文献+

Avastin和地塞米松在大鼠角膜新生血管中的作用 被引量:7

Effects of avastin and dexamethasone on rat corneal neovascularization
下载PDF
导出
摘要 目的探讨眼表应用avastin、地塞米松及联合用药对SD大鼠角膜新生血管(CNV)的作用及机制。方法建立碱烧伤诱导大鼠CNV模型,分为4组:地塞米松组给予质量分数0.1%地塞米松局部点眼;avastin组给予5.0g/Lavastin;联合组给予5.0g/Lavastin+0.1%地塞米松;对照组给予生理盐水。采用裂隙灯观察、免疫组织化学染色等方法观察各组CNV的面积和血管内皮生长因子(VEGF)的表达。结果第6天时,对照组CNV生长接近高峰,血管粗大、密集,交织成网状;地塞米松组和avastin组CNV较短,血管稀疏、细长;联合组CNV较短,血管较稀疏、细小。实验后3、6、12d,3个组CNV面积比较差异均有统计学意义(F=145.659,P=0.000;F=296.370,P=0.000;F=148.008,P=0.000),组间多重比较显示avastin组、地塞米松组及联合组CNV面积均小于对照组,差异均有统计学意义(P<0.01)。Avastin组与地塞米松组间差异无统计学意义(P>0.05)。第7天时,组织病理学检测显示对照组角膜可见大量炎性细胞浸润,基质层大量CNV,胶原纤维排列紊乱;地塞米松组、avastin组角膜基质排列趋于整齐,CNV明显减少,腔小且分布稀疏,未见大量炎性细胞浸润;联合组基质层胶原纤维排列规则,CNV显著减少,炎性细胞浸润较少。免疫组织化学检测提示对照组角膜全层VEGF表达明显增强,其表达部位主要分布在CNV区域和上皮全层。地塞米松组和avastin组CNV密度减低,角膜基质层CNV区域的VEGF表达减少;联合组CNV密度明显减低,VEGF表达微弱。结论 Avastin和地塞米松均能抑制CNV,二者联合用药具有协同作用,可降低CNV和炎性细胞浸润。 Background A variety of factors are related with corneal neovascularization(CNV),and vascular endothelial growth factor(VEGF) plays the regulative role in the forming process of CNV.Objective This study attempted to investigate the effect of topically administered agents avastin,dexamethasone and drug combination on experimental CNV and its mechanism in rats.Methods CNV animal models were induced by putting the 3 mm filter paper soaked 1 mol/L NaOH solution at the center cornea for 30 seconds in 48 clean SD rats.20 μL of avastin (5 g/L),20 μL of dexamethasone (0.1%),avastin+dexamethasone and 20 μL of 0.9%NaCl were topically applied respectively in 12 models at 5-minute interval for 12 days.The growth of CNV was observed under the slit lamp,and the CNV area was calculated.Hematoxylin-eosin staining of cornea samples was performed for the pathological examination on the seventh day after experiment.Expression of VEGF in CNV was detected by immunohistochemistry.Results In 12 days after experiment,corneal new blood vessels were dense and thicker in 0.9% NaCl solution group,but in 0.1% dexamethasone group and avastin group,the corneal new blood vessels were sparse and thinner.Less corneal new blood vessels were seen in avastin+dexamethasone group.The area of CNV was smaller in 0.1% dexamethasone group and avastin+dexamethasone group and avastin group in 3,6 and 12 days after experiment in comparison with 0.9% NaCl solution group (all P0.01).The area of CNV was significantly decreased in avastin group compared with 0.1% dexamethasone group and avastin+dexamethasone group in various time points (all P0.01).No significant difference in CNV area was found between 0.1% dexamethasone group and avastin group (P0.05).Infiltration of lots of inflammatory cells and vascular canals were seen in 0.9% NaCl solution group,but little of inflammatory cells and vascular canals were in dexamethasone group,avastin group and avastin+dexamethasone group.Immunohistochemistry revealed that the expression of VEGF was mainly in CNV zone and corneal epithelial layer.Expression of VEGF was more in 0.9% NaCl group compared with dexamethasone group and avastin group,and that in avastin+dexamethasone group was weaker.Conclusion Topical application of avastin and dexamethasone can inhibit alkali-induced CNV.Avastin and dexamethasone show a synergistic effect in suppressing the expression of VEGF and inflammation cells.
作者 沙翔垠 宋莉
出处 《眼科研究》 CSCD 北大核心 2010年第7期591-595,共5页 Chinese Ophthalmic Research
基金 广东省科技计划项目(2008B030301251)
关键词 角膜新生血管 AVASTIN 地塞米松 血管内皮生长因子 corneal neovascularization avastin dexamethasone vascular endothelial growth factor
  • 相关文献

参考文献16

  • 1Adamis AP,Shima DT.The role of vascular endothelial growth factor in ocular health and disease[J].Retina,2005,25(2):111-118.
  • 2Ferra N,Houck K,Jakeman L,et al.Molecular and biological properties of the vascular endothelial growth factor family of proteins[J].Endocr Rev,1992,13(1):18-32.
  • 3Miller KD,Chap LI,Holmes FA,et al.Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer[J].Clin Oncol,2005,23(4):792-799.
  • 4Yang JC,Haworth L,Sherry RM,et al.A randomized trial of bevacizumab,an anti-VEGF antibody,for metastatic renal cancer[J].N Engl J Med,2003,349(5):427-434.
  • 5Kang S,Chung SK.The effect of subconjunctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits[J].Cornea,2010,29(2):192-196.
  • 6赵峰,徐建江,郑天玉,王欣,林志荣,李纲,王文韬.贝伐单抗抑制角膜新生血管的实验研究[J].眼科研究,2009,27(11):983-987. 被引量:1
  • 7Bahar I,Kaiserman I,McAllum P,et al.Subconjunctival bevacizumab injection for corneal neovascularization[J].Cornea,2008,27(2):142-147.
  • 8Nakao S,Hata Y,Miura M,et al.Dexamethasone inhibits interleukin-1β-induced corneal neovascularization[J].Am J Pathol,2007,171(3):1058-1065.
  • 9Biswas PS,Banerjee K,Kinchington PR,et al.Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection[J].Exp Eye Res,2006,82(1):46-54.
  • 10Lu P,Li L,Liu G,et al.Opposite roles of CCR2 and CX3CR1 macrophages in alkali-induced corneal neovascularization[J].Cornea,2009,28(5):562-569.

二级参考文献16

  • 1严宏,刘兵,俞兰,王为农.糖皮质激素对α-晶状体蛋白分子伴侣功能的影响[J].眼科研究,2005,23(1):37-39. 被引量:4
  • 2戴超,卞修武,史景泉.诺帝抑制糖尿病大鼠视网膜VEGF和iNOS的表达及意义[J].第三军医大学学报,2005,27(12):1232-1235. 被引量:13
  • 3Mahoney JM,Waterbury LD.Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea[J].Curr Eye Res,1985,4:531-535.
  • 4Im SA,Gomez-Manzano C,Fueyo J,et al.Antiangiogenesis treatment for gliomas transfer of antisense vascular endothelial growth factor inhibits tumor growth in vivo[J].Cancer Res,1999,59(4):895-900.
  • 5Singh N,Amin S,Richter E,et al.Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo[J].Invest Ophthalmol Vis Sci,2005,46(5):1647-1652.
  • 6Rosenfeld PJ,Schwartz SD,Blumenkranz MS,et al.Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration[J].Ophthalmology,2005,112:1048-1053.
  • 7Michels S,Rosenfeld PJ,Puliafito CA,et al.Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration:Twelve-week results of an uncontrolled open-label clinical study[J].Ophthalmology,2005,112:1035-1047.
  • 8Rosenfeld PJ,Moshfeghi AA,Puliafito CA.Optical coherence tomography findings after intravitreal injection of bevacizumab(Avastin) for neovascular age-related macular degeneration[J].Ophthal Surg Lasers Imaging,2005,36:331-335.
  • 9Nguyen QD,Shah S,Tatlipinar S,et al.Bevacizumab suppresses choroidal neovascularization caused by pathological myopia[J].Br J Ophthalmol,2005,89:1368-1370.
  • 10Bock F,Onderka J,Dietrich T,et al.Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis[J].Invest Ophthalmol Vis Sci,2007,48:2545-2552.

共引文献12

同被引文献102

  • 1肖启国,刘祖国,张梅,郑健樑,张志红,罗丽辉,陈家祺.多西环素对培养的人结膜上皮细胞炎性反应及凋亡的影响[J].中华眼科杂志,2005,41(9):842-846. 被引量:7
  • 2赵卉,易正芳,胡宏慧,许迅.生物信息学筛选的合成小肽抑制小鼠角膜新生血管的实验研究[J].中华眼科杂志,2007,43(2):151-157. 被引量:5
  • 3Gimbrone MA, Leapman SB, Cotran RS, et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med, 1972, 136 : 261-276.
  • 4Ryan SJ. The development of an experimental model of sub-retinal neovascularization in disciform macular degeneration. Trans Am Ophthalmol Soc, 1979, 77: 707-745.
  • 5Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol, 1995, 113 : 810-818.
  • 6Virdi PS, Hayreh SS. Ocular neovascularization with retinal vascular occlusion. I. Association with experimental retinal vein occlusion. Arch Ophthalmol, 1982, 100 : 331-341.
  • 7Kenyon BM, Voest EE, Chen CC, et al. A model of angiogenesis in the mouse cornea. Invest OphthalmoI Vis Sci, 1996, 37: 1625- 1632.
  • 8Poche RA, Saik JE, West JL, et al. The mouse cornea as a trans- plantation site for live imaging of engineered tissue constructs. Cold Spring Harb Protoe, 2010 ( April), doi: 10. ll01/pdb. prot5416.
  • 9Rogers MS, Birsner AE, D'Amato RJ. The mouse cornea micro- pocket angiogenesis assay. Nat Protoc, 2007, 2: 2545-2550.
  • 10Corrent G, Roussel TJ, Tseng SC, et al. Promotion of graft survival by phntothrombotic occlusion of corneal neovascularization. Arch Ophthalmol, 1989, 107: 1501-1506.

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部